USES SKYRIZI is a prescription medicine used to treat adults with: moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using …

Jun 18, 2024 · The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach …

Nov 11, 2025 · Skyrizi (risankizumab) is an injection used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease. Includes indications, doses, interactions, side …

Jul 23, 2024 · As a treatment for ulcerative colitis, Skyrizi works by fighting the inflammation that can lead to symptoms of the disease.

SKYRIZI® is indicated for the treatment of moderately to severely active ulcerative colitis in adults. See Important Safety and Prescribing Information.

Jun 19, 2024 · The US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa; AbbVie) for the treatment of moderately to severely active ulcerative colitis in adults. This …

4 days ago · Effective 1/1/24 09/11/2024 – Reviewed and updated for September P&T. Added criteria for ulcerative colitis. Updated approval length for Skyrizi IV to 8 weeks.

Jun 20, 2024 · The FDA has given its okay to the biologic drug Skyrizi (risankizumab) as a treatment for people with moderately to severely active ulcerative colitis. The medication works …

Risankizumab-rzaa (SKYRIZI) in Ulcerative Colitis National Drug Monograph February 2025 VA Pharmacy Benefits Management Services and National Formulary Committee The purpose of …

Risankizumab, sold under the brand name Skyrizi (/ skaɪˈrɪzi / sky-RIZZ-ee), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's …